UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 2, 2023 Bellicum Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter) | | | | | | | | | | | | | | |
| Delaware | | 001-36783 | | 20-1450200 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | | |
3730 Kirby Drive, Ste. 1200, Houston, TX 77098
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 281-454-3424
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | BLCM | The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023. In connection with the termination of Mr. Fair’s employment, he will receive severance benefits in accordance with his employment agreement. In connection with the termination of Dr. Scripture’s employment, she will receive severance benefits in accordance with her employment agreement and she will receive COBRA reimbursement for up to 12 months. Payment of severance benefits for each individual is conditioned upon them providing a general release of claims for the benefit of the Company following his or her last day of employment. Each of these officers will enter into consulting agreements with the Company to continue to provide services in their officer capacities as consultants to the Company and will be paid hourly for their services. The Company intends to file the consulting agreements as exhibits to the Company’s Quarterly Report on Form 10Q for the second quarter of 2023.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | | | | | | | |
| | | | | |
| | | Bellicum Pharmaceuticals, Inc. |
| | | |
| Dated: June 2, 2023 | | | By: | | /s/ Richard A. Fair |
| | | | | Richard A. Fair |
| | | | | President and Chief Executive Officer |
| | | | | |
